Molecular prognostication in bladder cancer--a current perspective

Eur J Cancer. 2003 Jul;39(11):1501-10. doi: 10.1016/s0959-8049(03)00300-9.


The optimal management of bladder cancer depends on the accurate assessment of the tumour's biological potential. Advances in molecular biology and cytogenetics have spurred intense research in identifying and characterising prognostic markers for patients with transitional cell carcinoma (TCC) of the bladder. The molecular changes that occur can be categorised into (1) chromosomal alterations leading to carcinogenesis, (2) cellular proliferation as a result of dysregulation of cell cycle control, and (3) growth control processes such as angiogenesis leading to metastasis. The accumulation of these changes ultimately determines a tumour's clinical behaviour and response to therapy. As the understanding of bladder cancer evolves, novel molecular markers for prognostication will make their way from the research laboratory to the clinical setting with the promise to improve patient care and outcomes.

Publication types

  • Review

MeSH terms

  • Biomarkers, Tumor / analysis
  • Carcinoma, Transitional Cell / blood supply
  • Carcinoma, Transitional Cell / genetics*
  • Cell Adhesion
  • Cell Cycle / genetics
  • Forecasting
  • Humans
  • Neovascularization, Pathologic / genetics
  • Oncogenes / genetics*
  • Prognosis
  • Urinary Bladder Neoplasms / blood supply
  • Urinary Bladder Neoplasms / genetics*


  • Biomarkers, Tumor